Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KUR-502 |
Synonyms | |
Therapy Description |
Limited information is available on KUR-502, a putative cell therapy comprising allogeneic natural killer T-lymohocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KUR-502 | KUR 502|KUR502|CMD 502 | CD19 Immune Cell Therapy 62 | Limited information is available on KUR-502, a putative cell therapy comprising allogeneic natural killer T-lymohocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05487651 | Phase I | KUR-502 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2) | Recruiting | USA | 0 |